A2RL
23.4.2024 17:55:33 CEST | Business Wire | Press release
On Saturday, April 27th, Abu Dhabi will host a groundbreaking event, welcoming 10,000 spectators to witness the inaugural ASPIRE Abu Dhabi Autonomous Racing League (A2RL) at the iconic Yas Marina Circuit. This brand-new autonomous racing competition marks a significant milestone in motorsport history, billed as the largest league of its kind globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423980323/en/
Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 27 (Photo: AETOSWire)
Eight teams will compete: Code19 Racing (one of the first independent autonomous racing entity from the USA), Constructor University (based in Germany and Switzerland), Fly Eagle (representing Beijing Institute of Technology from China and Khalifa University from the UAE), HUMDA Lab (a member of the Széchenyi István University Group from Hungary), KINETIZ (a collaboration between Singapore Nanyang Technological University and Kintsugi based in the UAE), PoliMOVE (representing Politecnico di Milano from Italy), UNIMORE (also from Italy - University of Modena and Reggio Emilia), and Technical University of Munich - TUM (from Germany), vying for a substantial prize purse of US$ 2.25 million.
The participating teams of coders and engineers will each have exclusive access to identical Dallara Super Formula SF23 cars, made possible through a partnership with Japan Race Promotions. These cars will be autonomized with autonomous racing stacks developed and integrated by the Technology Innovation Institute (TII). The sole variable lies in how each team utilizes their coding skills, AI algorithms, and machine learning software development expertise to teach their cars how to drive. Currently recognized as the fastest open-wheel race car in the world after Formula One, these cars can reach speeds of up to 300 km/h.
For the first time, the race format is poised to feature four autonomous cars driving on the racetrack simultaneously – a feat never before attempted. In a series of pre-qualifying races, the finale will showcase the top performers from the Lap Test and Speed Test, advancing to a final Overtaking Challenge to determine the ultimate winner. Additionally, an AI vs Human car race will unfold, with the Technology Innovation Institute (TII) embracing the electrifying challenge of pitting their autonomous car against former F1 driver – Daniil Kvyat. TII will aim to get as close as possible to the human lap time and will also demonstrate the autonomous car’s ability to drive without GPS assistance.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council - ASPIRE’s parent entity, and Advisor to the UAE President on Strategic Research and Advanced Technology Affairs, said: "In pushing the boundaries of technology under extreme conditions, we uncover new frontiers in science. This reimagined racing paradigm harnesses the pinnacle of coding skills, AI algorithms, and software development prowess — the very skill sets of the future. By leveraging these capabilities, we pave a path at the forefront of research and development, propelling Abu Dhabi to become a pivotal global hub for innovation."
ADNOC has come on board as title sponsor, providing crucial support, underscoring the widespread enthusiasm for advancing autonomous racing technology. H.E. Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, and Group MD & CEO of ADNOC, added: "As we navigate the path to UAE's industrial future, our commitment to in-country value and technological advancement stands unwavering. A2RL epitomizes our dedication to integrating cutting-edge technology including AI, driving competitiveness and economic growth across sectors. For decades, ADNOC has invested in the latest technology and innovation – from the control room, to the board room - to deliver the modern energy that powers our lives."
Organizer of A2RL, ASPIRE CEO Stephane Timpano said: "A2RL is more than just a race — it's a platform for testing and optimizing autonomous vehicle technologies, enhancing safety and reliability on public roads. With the support of local and international partners, we're bringing the mobility future - closer." The inaugural race has attracted a diverse array of sponsors, each contributing their expertise and resources to ensure the success of the development of the cutting-edge autonomized cars. Leading partners, such as Du, DMT, AWS, and Mubadala, have played pivotal roles in shaping the event’s trajectory, with media partners such Motorsports, Inc. Arabia, FastCompany Middle East, and What’s On, amplifying A2RL’s visibility.
Technical partners, including Dallara, Danisi Engineering, Meccanica 42, Kistler, Seyond, Eventagrate, Live in Five, Focal Point VR and Vislink, have lent their specialized knowledge to elevate the event's innovation and performance standards.
An exclusive Fan Zone promises an elevated experience for families, motorsport fans, and tech enthusiasts alike. With tailored activities, guests can immerse themselves in cutting-edge tech and gaming, including a captivating VR zone and the AI museum – Raceum. From 16:00 (GST) on April 27, young students from the A2RL STEM Competition will showcase their coding skills on 1:8 scale autonomous racing cars, with 18 schools competing to add excitement. The night concludes at 23:00 (GST), with activities including a podium ceremony for the winners, fireworks, a drone show, and an after-show concert with DJ Andre Soueid.
For those unable to attend in person, the excitement of Race Day will be accessible through various live streaming channels, including A2RL’s official YouTube and Twitch channels, motorsport.tv and the A2RL app. Interested parties are invited to visit the A2RL website and monitor social media channels for updates regarding the program schedule and details on viewing the race in their respective regions.
The inaugural A2RL event is part of Abu Dhabi Mobility Week, running from April 24 to May 1.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423980323/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
